AstraZeneca, Karolinska Institutet collaborate on molecular imaging research

Thursday, June 21, 2012 04:29 PM

Global biopharmaceutical company AstraZeneca and Karolinska Institutet, a medical university in Sweden, have entered into a three year collaborative research agreement that will apply state-of-the-art molecular imaging technologies to generate novel diagnostic imaging tools and further the development of AstraZeneca’s neuroscience R&D pipeline.

AstraZeneca and Karolinska Insitutet have collaborated since 2006 in the field of positron emission tomography (PET), a modern imaging technique allowing for non-invasive examination of the human brain. This joint venture and application of complementary capabilities has led to the invention of numerous novel PET ligands, as well as aided in the development of a number of drug development programs. Continued collaboration between AstraZeneca and the university is expected to deliver new imaging tools for the diagnosis of patients primarily with severe neurological illnesses as well as in pain control. In addition, the alliance will facilitate the development of drugs for disorders such as chronic pain, Alzheimer’s and Parkinson’s disease, where there is an urgent need for new treatments.

AstraZeneca scientists will supply the technologies and skills required to synthesize and develop new imaging molecules, while the PET Centre at Karolinska Institutet will provide radiochemistry for labeling of the imaging molecules and the PET-studies required to support and facilitate AstraZeneca projects.

“Demonstrating robust target engagement is one of the critical success criteria for transitioning molecules through early research and development. Working with our colleagues from Karolinska Institutet will help us identify and develop new PET ligands and accelerate our efforts to deliver novel medicines to patients,” said Menelas Pangalos, executive vice president of innovative medicines, AstraZeneca.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs